IL243569A - Lentiviral gene transfer vectors and their medicinal applications - Google Patents

Lentiviral gene transfer vectors and their medicinal applications

Info

Publication number
IL243569A
IL243569A IL243569A IL24356916A IL243569A IL 243569 A IL243569 A IL 243569A IL 243569 A IL243569 A IL 243569A IL 24356916 A IL24356916 A IL 24356916A IL 243569 A IL243569 A IL 243569A
Authority
IL
Israel
Prior art keywords
cells
vector
vsv
lentiviral
gag
Prior art date
Application number
IL243569A
Other languages
English (en)
Hebrew (he)
Inventor
Charneau Pierre
Beignon Anne-Sophie
Philippe Coutant Frederic
Courbeyrette Karine
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Theravectys
Charneau Pierre
Beignon Anne-Sophie
Philippe Coutant Frederic
Courbeyrette Karine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07290980.7A external-priority patent/EP2020444B1/en
Priority claimed from EP07291251.2A external-priority patent/EP2047861B1/en
Application filed by Pasteur Institut, Centre Nat Rech Scient, Theravectys, Charneau Pierre, Beignon Anne-Sophie, Philippe Coutant Frederic, Courbeyrette Karine filed Critical Pasteur Institut
Publication of IL243569A publication Critical patent/IL243569A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1143—
    • C07K16/116—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL243569A 2007-08-03 2016-01-11 Lentiviral gene transfer vectors and their medicinal applications IL243569A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07290979 2007-08-03
EP07290980.7A EP2020444B1 (en) 2007-08-03 2007-08-03 Defective non-integrative lentiviral transfer vectors for vaccines
EP07291251.2A EP2047861B1 (en) 2007-10-12 2007-10-12 Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications
EP08156405 2008-05-16
PCT/IB2008/002930 WO2009019612A2 (en) 2007-08-03 2008-08-01 Lentiviral gene transfer vectors and their medicinal applications

Publications (1)

Publication Number Publication Date
IL243569A true IL243569A (en) 2016-07-31

Family

ID=40341833

Family Applications (1)

Application Number Title Priority Date Filing Date
IL243569A IL243569A (en) 2007-08-03 2016-01-11 Lentiviral gene transfer vectors and their medicinal applications

Country Status (14)

Country Link
US (3) US8420104B2 (enExample)
EP (1) EP2185192B1 (enExample)
JP (3) JP5773648B2 (enExample)
CN (2) CN102083462B (enExample)
AU (1) AU2008285224B2 (enExample)
BR (1) BRPI0813194B8 (enExample)
CA (1) CA2695433C (enExample)
DK (1) DK2185192T3 (enExample)
ES (1) ES2708856T3 (enExample)
HK (1) HK1252608A1 (enExample)
IL (1) IL243569A (enExample)
MX (2) MX342449B (enExample)
PT (1) PT2185192T (enExample)
WO (1) WO2009019612A2 (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
ES2708856T3 (es) 2007-08-03 2019-04-11 Pasteur Institut Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales
EP2427577A4 (en) * 2009-05-04 2013-10-23 Hutchinson Fred Cancer Res PSEUDOTYPED RETROVIRAL VECTORS WITH COCAL VESICULOVIRUS SHELL
EP2366776A1 (en) * 2010-03-01 2011-09-21 Epixis A method for measuring viral infectivity
DK2385107T3 (en) 2010-05-03 2016-12-12 Pasteur Institut Lentiviral vector-based immunological compounds against malaria
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
EP2576772B1 (en) 2010-05-26 2018-12-12 Deutsches Rheuma-Forschungszentrum Berlin Antigen-presenting modified naïve b cells for immune suppression and a method for producing said modified cells
CN102277380B (zh) * 2010-06-08 2013-03-27 齐鲁制药有限公司 一种dhfr互补表达的共转染真核表达载体及其制备方法与应用
CA2803543A1 (en) 2010-06-25 2011-12-29 Omarco Network Solutions Limited Security improvements for flexible substrates
EP2643343A1 (en) 2010-11-26 2013-10-02 Institut Pasteur Identification of a human gyrovirus and applications.
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2788477A2 (en) 2011-12-07 2014-10-15 Institut Pasteur Identification of a swine parecho-like virus and applications
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2013140169A1 (en) * 2012-03-20 2013-09-26 Isis Innovation Limited Immunogenic composition and methods of use thereof
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
EP2831095B1 (en) 2012-03-30 2018-11-28 Immune Design Corp. Lentiviral vector particles having improved transduction efficiency for cells expressing dc-sign
WO2014016383A2 (en) 2012-07-25 2014-01-30 Theravectys Glycoproteins for pseudotyping lentivectors
FR2996856B1 (fr) * 2012-10-15 2015-06-05 Agronomique Inst Nat Rech Novirhabdovirus recombinant utilisable comme vecteur d'antigenes
AU2013358922B2 (en) 2012-12-14 2019-08-22 The Regents Of The University Of California Viral vector nanocapsule for targeting gene therapy and its preparation
SG11201509743WA (en) * 2013-06-03 2015-12-30 Theravectys Lentiviral vectors containing an mhc class i, mhc class ii, or beta-2 microglobulin upstream promoter sequence
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
WO2015063708A1 (en) * 2013-10-31 2015-05-07 Theravectys LENTIVIRAL VECTORS FOR INDUCING CD4+ and CD8+ IMMUNE RESPONSES IN VACCINATION OF HUMANS INFECTED WITH HIV-1
EP3009144A1 (en) * 2014-10-15 2016-04-20 Theravectys Lentiviral vectors for inducing CD4+ and CD8+ immune responses in vaccination of humans
EP2878674A1 (en) * 2013-11-28 2015-06-03 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Stable episomes based on non-integrative lentiviral vectors
EP2878667A1 (en) 2013-11-29 2015-06-03 Institut Pasteur TAL effector means useful for partial or full deletion of DNA tandem repeats
KR20160111973A (ko) * 2014-01-27 2016-09-27 떼라벡띠스 인간 t 림프영양성 바이러스 타입 1에 대한 면역 반응들을 발생시키기 위한 렌티바이러스 벡터들
CN106794240A (zh) * 2014-03-01 2017-05-31 普罗菲克图斯生物科学股份有限公司 重组伊斯法罕病毒载体
AU2015311707B2 (en) 2014-09-07 2021-12-09 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
EP3211003A1 (en) 2016-02-24 2017-08-30 Institut Pasteur T cell receptors from the hiv-specific repertoire, means for their production and therapeutic uses thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3235828A1 (en) 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
US10870865B2 (en) * 2016-05-13 2020-12-22 Flash Therapeutics Particle for the encapsidation of a genome engineering system
CN106399376A (zh) * 2016-08-31 2017-02-15 河南省华隆生物技术有限公司 一种整合缺陷型慢病毒载体、其制备方法及应用
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
JP2020506695A (ja) 2017-01-30 2020-03-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 糖原病を処置するための組換えウイルスベクター
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
MX2019011599A (es) 2017-03-30 2019-12-19 Univ Queensland Moleculas quimericas y usos de las mismas.
FR3065967B1 (fr) * 2017-05-05 2022-06-03 Univ Paris Descartes Procede in vitro de detection et de quantification de l'adn du vih-2
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019040994A1 (en) 2017-09-01 2019-03-07 The Australian National University IMMUNOREGULATOR MOLECULES AND USES THEREOF
HUE069207T2 (hu) 2017-09-22 2025-02-28 Centre Nat Rech Scient A vesicularis stomatitis vírus mutált glikoproteinje
CN117180442A (zh) * 2017-09-28 2023-12-08 天腾有限公司 用于治疗癌症的新型的基于重组质膜的囊泡
JP6994714B2 (ja) 2017-10-03 2022-01-14 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
WO2019077150A1 (en) * 2017-10-20 2019-04-25 Genethon USE OF SYNCYTIN TO TARGET A MEDICINAL PRODUCT AND GENE ADMINISTRATION TO PULMONARY TISSUE
AU2018365296B2 (en) 2017-11-09 2023-11-23 Institut Pasteur A Zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
IL276957B2 (en) 2018-02-26 2023-12-01 Antolrx Inc Tolerogenic liposomes and methods of using them
JP6917942B2 (ja) 2018-04-11 2021-08-11 株式会社日立製作所 データ分析サーバ、データ分析システム、及びデータ分析方法
CN110577585A (zh) * 2018-06-07 2019-12-17 中国医学科学院基础医学研究所 水泡型口炎病毒包膜糖蛋白变体及其构建方法和应用
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020086742A1 (en) 2018-10-24 2020-04-30 Obsidian Therapeutics, Inc. Er tunable protein regulation
WO2020115114A1 (en) * 2018-12-04 2020-06-11 Sirion Biotech Gmbh Viral transduction using poloxamines
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021010840A (es) 2019-03-08 2022-01-19 Obsidian Therapeutics Inc Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
EP3708176A1 (en) * 2019-03-15 2020-09-16 Centre National De La Recherche Scientifique -Cnrs- Mutant vsv ectodomain polypeptide and uses thereof
CA3130488A1 (en) 2019-03-19 2020-09-24 David R. Liu Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CA3138525A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
US20240124889A1 (en) 2019-05-07 2024-04-18 Voyager Therapeutics, Inc. Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
EP3976802A1 (en) 2019-05-28 2022-04-06 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
EP3770264A1 (en) 2019-07-22 2021-01-27 Genethon Precise integration using nuclease targeted idlv
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021180665A1 (en) * 2020-03-09 2021-09-16 Janssen Pharmaceutica Nv Compositions and methods for quantifying integration of recombinant vector nucleic acid
CN111593073B (zh) * 2020-03-18 2022-03-08 睿丰康生物医药科技(浙江)有限公司 双报告基因骨架载体、四质粒假病毒包装系统、包装新冠肺炎假病毒
US20230365989A1 (en) * 2020-03-20 2023-11-16 The Broad Institute, Inc. Compositions and methods for enhanced lentiviral production
MX2023001028A (es) 2020-07-24 2023-04-24 Massachusetts Gen Hospital Particulas similares a virus potenciadas y metodos de uso de las mismas para suministro a celulas.
EP4208175A4 (en) * 2020-09-01 2025-05-07 The Trustees of The University of Pennsylvania IMPROVED GENERATION OF T-CELL TRANSDUCING LENTIVIRAL VECTORS USING A COCAL ENVELOPE
KR102379144B1 (ko) * 2020-09-29 2022-03-28 한국표준과학연구원 SARS-CoV-2의 RNA 표준물질 및 이를 이용한 코로나19바이러스(SARS-CoV-2) 감염 진단 정보의 제공방법
KR102283733B1 (ko) * 2020-12-22 2021-08-02 한국표준과학연구원 ＣＯＶＩＤ-19 바이러스 진단을 위한, ＳＡＲＳ-ＣｏＶ-2 포장 ＲＮＡ 표준물질, 이의 제조방법 및 이의 용도
WO2022165262A1 (en) * 2021-01-28 2022-08-04 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
CN114107393A (zh) 2021-04-07 2022-03-01 上海劲威生物科技有限公司 一种治疗乙型肝炎的慢病毒载体、慢病毒颗粒及其制备方法和应用
TWI758171B (zh) 2021-04-28 2022-03-11 沛爾生技醫藥股份有限公司 慢病毒包裝系統及使用其以提高宿主細胞之慢病毒產量的方法
CN115247190B (zh) * 2021-04-28 2024-06-18 沛尔生技医药股份有限公司 慢病毒包装系统、其所制得的慢病毒及经该慢病毒转导的细胞及其应用
WO2022235929A1 (en) 2021-05-05 2022-11-10 Radius Pharmaceuticals, Inc. Animal model having homologous recombination of mouse pth1 receptor
AU2022301302A1 (en) 2021-07-01 2024-01-25 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
JP2024534771A (ja) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞
US20250127820A1 (en) 2021-08-11 2025-04-24 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
CA3227108A1 (en) 2021-08-11 2023-02-16 Xiaomeng HU Genetically modified primary cells for allogeneic cell therapy
EP4384544A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
KR20240124919A (ko) * 2021-11-15 2024-08-19 떼라벡띠스 인유두종 바이러스 항원의 발현을 위한 렌티바이러스 벡터 및 이의 hpv 유발 암 치료에 대한 구현
CN114181972A (zh) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体
EP4448776A1 (en) 2021-12-16 2024-10-23 Ludwig Institute for Cancer Research Ltd Antisense transfer vectors and methods of use thereof
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023158836A1 (en) 2022-02-17 2023-08-24 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
AU2023299307A1 (en) 2022-06-30 2025-01-09 Indapta Therapeutics, Inc. Combination of engineered natural killer (nk) cells and antibody therapy and related methods
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
CA3263030A1 (en) * 2022-07-27 2024-02-01 Institut Pasteur Lentiviral vectors for the expression of human papillomavirus (HPV) antigens and their use in the treatment of HPV-induced cancers
CN116024269B (zh) * 2022-11-18 2024-02-02 复百澳(苏州)生物医药科技有限公司 一种冠状病毒假病毒颗粒的制备方法
WO2024129696A1 (en) 2022-12-12 2024-06-20 Retromer Therapeutics Corp. Aav and lentiviral constructs comprising a sorl1 mini-gene for use in treating neurodegenerative diseases
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
EP4649162A1 (en) * 2023-01-10 2025-11-19 Legend Biotech Ireland Limited Regulatory sequences and uses thereof
WO2024178386A1 (en) 2023-02-24 2024-08-29 Aarhus Universitet Methods of treating endosomal trafficking diseases
CN121001739A (zh) * 2023-04-13 2025-11-21 深圳市济因生物科技有限公司 一种载体及其应用
WO2024226784A2 (en) * 2023-04-27 2024-10-31 Genvivo, Inc. Compositions and methods for therapeutic or vaccine delivery
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
US12440564B2 (en) 2023-09-25 2025-10-14 Kelonia Therapeutics, Inc. Compositions for treating cancer
CN119639818A (zh) * 2025-02-18 2025-03-18 南京市计量监督检测院 一种假病毒颗粒的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2169073E (pt) * 1999-10-11 2014-02-20 Pasteur Institut Vectores para a preparação de composições imunoterapêuticas
WO2001092508A1 (en) * 2000-06-01 2001-12-06 Dnavec Research Inc. Pseudo-type retrovirus vector containing membrane protein having hemagglutinin activity
AU9456201A (en) 2000-09-15 2002-03-26 Merck & Co Inc Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
US7575924B2 (en) * 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
AP2368A (en) 2001-05-03 2012-02-27 Fit Biotech Oyj Plc Novel expression vectors and uses thereof.
CA2449589A1 (en) 2001-06-08 2002-12-19 Dnavec Research Inc. Gene transfer into primate embryonic stem cells using vsv-g pseudotyped simian immunodeficiency virus vector
EP1444350B1 (en) 2001-10-31 2013-06-19 The South African Medical Research Council Hiv-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof
WO2004110485A1 (en) * 2003-06-13 2004-12-23 Palmowski Michael J Materials and methods for improved vaccination
WO2005028634A2 (en) 2003-09-18 2005-03-31 Emory University Improved mva vaccines
FR2872170B1 (fr) * 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
KR101253363B1 (ko) * 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 개선된 아데노바이러스 벡터 및 그것의 용도
EP1888758A2 (en) * 2005-05-20 2008-02-20 VIRxSYS Corporation Transduction of primary cells
US20070020238A1 (en) * 2005-06-01 2007-01-25 David Baltimore Method of targeted gene delivery using viral vectors
ES2281252B1 (es) * 2005-07-27 2009-02-16 Consejo Superior De Investigaciones Cientificas Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapeuticas contra el sida.
ZA200803883B (en) 2005-11-08 2009-07-29 South African Medical Research Council Chimaeric HIV-1 subtype C Gag-virus-like particles
JP2009520790A (ja) 2005-12-21 2009-05-28 グラクソ グループ リミテッド 免疫応答を惹起する方法
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
WO2007091066A1 (en) 2006-02-07 2007-08-16 Ucl Business Plc Applications of non-integrating lentiviral vectors
ES2708856T3 (es) * 2007-08-03 2019-04-11 Pasteur Institut Vectores de transferencia de gen lentivírico y sus aplicaciones medicinales

Also Published As

Publication number Publication date
PT2185192T (pt) 2019-02-12
JP2015062425A (ja) 2015-04-09
ES2708856T3 (es) 2019-04-11
CN102083462B (zh) 2015-02-18
WO2009019612A3 (en) 2009-12-23
HK1252608A1 (zh) 2019-05-31
EP2185192B1 (en) 2018-10-31
JP5773648B2 (ja) 2015-09-02
US9328146B2 (en) 2016-05-03
EP2185192A2 (en) 2010-05-19
US20100297168A1 (en) 2010-11-25
AU2008285224A1 (en) 2009-02-12
US8709799B2 (en) 2014-04-29
BRPI0813194B1 (pt) 2020-05-05
BRPI0813194B8 (pt) 2021-05-25
US20140248306A1 (en) 2014-09-04
DK2185192T3 (en) 2019-02-18
JP2010535495A (ja) 2010-11-25
US20120315296A1 (en) 2012-12-13
CA2695433A1 (en) 2009-02-12
MX2010001379A (es) 2010-06-08
AU2008285224B2 (en) 2015-01-22
US8420104B2 (en) 2013-04-16
CN108114276A (zh) 2018-06-05
CN102083462A (zh) 2011-06-01
WO2009019612A2 (en) 2009-02-12
CA2695433C (en) 2025-05-06
JP6480028B2 (ja) 2019-03-06
MX342449B (es) 2016-09-29
BRPI0813194A2 (pt) 2016-11-01
JP2018076363A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
CA2695433C (en) Antiviral gene transfer vectors and their medicinal applications
JP6165612B2 (ja) コンセンサス／先祖免疫原
EP2047861B1 (en) Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications
EP2020444B1 (en) Defective non-integrative lentiviral transfer vectors for vaccines
AU2013203404B2 (en) Lentiviral gene transfer vectors and their medicinal applications
HK1140678B (en) Lentiviral gene transfer vectors and their medicinal applications
HK1140678A (en) Lentiviral gene transfer vectors and their medicinal applications
Gallinaro Integrase defective lentiviral vector as a vaccine platform for delivering HIV-1 antigens
HK1126146A (en) Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications
TW202423456A (zh) 表現選自denv、zikv及yfv之群之黃病毒之非結構抗原、誘導宿主中保護性cd8+t細胞免疫的多核苷酸及慢病毒載體
Bowder Contributions of the gp120 Variable Loops to Envelope Glycoprotein Trimer Stability in Primate Lentiviruses
MXPA06003076A (en) Consensus/ancestral immunogens

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed